BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells

INTRODUCTION: Venetoclax (VCX) is a selective BCL-2 inhibitor approved for the treatment of leukemia and lymphoma. However, the mechanisms of anti-cancer effect of VCX either as a monotherapy or in combination with other chemotherapeutic agents against breast cancer need investigation. METHODS: Brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhoshani, Ali, Alatawi, Fahad O, Al-Anazi, Fawaz E, Attafi, Ibraheem M, Zeidan, Asad, Agouni, Abdelali, El Gamal, Heba M, Shamoon, Licia S, Khalaf, Sarah, Korashy, Hesham M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783200/
https://www.ncbi.nlm.nih.gov/pubmed/33414642
http://dx.doi.org/10.2147/OTT.S281519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783200/
https://www.ncbi.nlm.nih.gov/pubmed/33414642
http://dx.doi.org/10.2147/OTT.S281519

Ejemplares similares